Harvard researchers have identified a precise biological pathway connecting a common gut bacterium to depression, pointing to an unexpected culprit: a contamination process that transforms harmless bacterial molecules into immune-activating triggers.
The bacterium Morganella morganii has appeared in multiple studies as a correlate of major depressive disorder, but scientists remained uncertain whether the microbe actually causes depression, whether depression alters the microbiome, or whether some third factor explained the association. The new work, published in the Journal of the American Chemical Society, offers a mechanistic answer that strengthens the case for direct causation.
Researchers at Harvard Medical School discovered that an industrial chemical called diethanolamine, or DEA, can contaminate molecules produced by M. morganii in the gut. When DEA substitutes for a sugar alcohol in these bacterial products, the altered molecules behave like cardiolipins, fatty compounds known to activate immune defenses. The result is a flood of inflammatory proteins called cytokines, particularly interleukin-6 or IL-6, that has been independently associated with depression in prior research.
"There is a story out there linking the gut microbiome with depression, and this study takes it one step further, toward a real understanding of the molecular mechanisms behind the link," said Jon Clardy, a senior author and professor of biological chemistry and molecular pharmacology at Harvard Medical School's Blavatnik Institute.
The finding emerged from an unexpected discovery during the research process. Clardy explained that scientists knew industrial chemicals could be incorporated into body fats but did not understand how this happened or what consequences followed. "DEA's metabolism into an immune signal was completely unexpected," he said.
The mechanism opens new diagnostic and treatment avenues. DEA could potentially serve as a biomarker to identify depression cases driven by this inflammatory pathway. Beyond that, the research suggests that immune-modulating drugs might help patients whose depression stems from this bacterial interaction, offering an alternative to traditional psychiatric treatments for at least some individuals.
The work represents a collaboration between two distinct research groups at Harvard Medical School and Massachusetts General Hospital. Clardy's lab specializes in the chemistry of molecules produced by bacteria, while Ramnik Xavier's group focuses on how the microbiome affects health at the molecular level. Together, they have documented similar mechanisms in other bacteria.
Recent collaborative findings show that the bacterium Akkermansia muciniphila produces molecules that protect against inflammation and enhance cancer immunotherapy responses. The gut bacterium Ruminococcus gnavus generates an immune-activating sugar chain linked to Crohn's disease and inflammatory bowel disease. The "strep throat" bacterium Streptococcus pyogenes carries a fatty molecule on its surface that triggers inflammatory cytokine release, helping explain severe immune complications and potential links to autoimmune conditions like lupus.
These discoveries establish a framework for investigating how other gut microbes influence human health through similar pathways. Clardy noted that the next step involves surveying additional bacteria to determine whether they employ comparable chemistry and to identify other examples of how bacterial metabolites affect human biology.
The research was funded by the National Institutes of Health and The Leona M. and Harry B. Helmsley Charitable Trust. Sunghee Bang and Yern-Hyerk Shin are co-first authors, with additional contributions from Sung-Moo Park, Lei Deng, R. Thomas Williamson, and Daniel B. Graham.
Author Jessica Williams: "This work finally gives us a tangible mechanism to explain why a specific gut bacterium keeps showing up in depression cases, and that clarity opens real doors for new treatments."
Comments